scholarly journals Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study

PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0178572 ◽  
Author(s):  
Marie Matignon ◽  
Caroline Pilon ◽  
Morgane Commereuc ◽  
Cynthia Grondin ◽  
Claire Leibler ◽  
...  
Keyword(s):  
Observational Study ◽  
Intravenous Immunoglobulin ◽  
Kidney Transplant ◽  
De Novo ◽  
Immunoglobulin Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Intravenous Immunoglobulin Therapy

Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study

2016 ◽  
Vol 29 (11) ◽  
pp. 1205-1215 ◽  
Author(s):  
Yosu Luque ◽  
Dany Anglicheau ◽  
Marion Rabant ◽  
Khalil El Karoui ◽  
Matthieu Jamme ◽  
...  
Keyword(s):  
Observational Study ◽  
Intravenous Immunoglobulin ◽  
Kidney Transplant ◽  
High Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Renal Safety

scholarly journals Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Aziza Ajlan ◽  
Hassan Aleid ◽  
Tariq Zulfiquar Ali ◽  
Hala Joharji ◽  
Khalid Almeshari ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
First Year ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Double Blind ◽  
Donor Specific Antibodies

Abstract Background Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first-line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the setting of tacrolimus-based immunosuppression has not been fully investigated. Aims To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC protocol. Methods Prospective, randomized, double blind, non-inferiority, controlled clinical trial Expected outcomes 1. Primary outcomes: Biopsy-proven acute rejection within first year following transplant 2. Secondary outcomes: a. Patient and graft survival at 1 year b. eGFR at 6 months and at 12 months c. Emergence of de novo donor-specific antibodies (DSAs) Trial registration The study has been prospectively registered at clinicaltrials.gov (NTC: 04404127). Registered on 27 May 2020.

Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus

2018 ◽  
Vol 20 (2) ◽  
pp. e12846 ◽  
Author(s):  
Arnaud Devresse ◽  
Marianne Leruez-Ville ◽  
Anne Scemla ◽  
Véronique Avettand-Fenoel ◽  
Lise Morin ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Late Onset ◽  
Antiviral Prophylaxis ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Primary Disease
Sign in / Sign up

Export Citation Format

Share Document